Dr. James A. Mansi is currently part of the Global Medical Affairs team for Seqirus, A CSL Company. He completed his doctoral studies in physiology/endocrinology at Université Laval in Québec City. Over the course of his career he has been involved with the development and introduction of several novel vaccines, most notably human rotavirus, human papillomavirus, zoster, and most recently invasive meningococcal disease caused by serogroup B and the MF59-adjuvanted seasonal influenza vaccine. His work and research has been primarily focused on addressing information and data gaps supporting decision making on such vaccine preventable diseases. Having spent the last 12 years in vaccine development and medical affairs he has nurtured a great passion and admiration for the science and art that embody vaccinology.